{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:47:27Z","timestamp":1791406047443,"version":"4.3.3"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jhep.2016.11.009","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T09:31:38Z","timestamp":1480066298000},"page":"685-692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"title":["Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5499-0391","authenticated-orcid":false,"given":"Satomi","family":"Shimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Watashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Fukano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Peel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Sluder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senko","family":"Tsukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko S.","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam-Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kusuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Sureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaji","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.11.009_b0005","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.3748\/wjg.v20.i11.2955","article-title":"Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection","volume":"20","author":"Liu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.11.009_b0010","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2016.11.009_b0015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1101\/cshperspect.a021535","article-title":"Treatment of liver cancer","volume":"5","author":"Liu","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jhep.2016.11.009_b0020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","volume":"479\u2013480","author":"Seeger","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2016.11.009_b0025","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1136\/gutjnl-2014-308943","article-title":"Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure","volume":"64","author":"Zeisel","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.11.009_b0030","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jhep.2014.05.016","article-title":"Bridging basic science and clinical research: the EASL Monothematic Conference on Translational Research in Viral Hepatitis","volume":"61","author":"Boettler","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.11.009_b0035","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/S1473-3099(15)00436-3","article-title":"New therapeutic agents for chronic hepatitis B","volume":"16","author":"Brahmania","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2016.11.009_b0040","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.gastro.2007.11.036","article-title":"Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach","volume":"134","author":"Pawlotsky","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.11.009_b0045","doi-asserted-by":"crossref","first-page":"g3308","DOI":"10.1136\/bmj.g3308","article-title":"Antiviral treatment of hepatitis C","volume":"348","author":"Feeney","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2016.11.009_b0050","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrmicro3098","article-title":"The ins and outs of hepatitis C virus entry and assembly","volume":"11","author":"Lindenbach","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jhep.2016.11.009_b0055","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jhep.2005.01.011","article-title":"What determines the natural history of recurrent hepatitis C after liver transplantation?","volume":"42","author":"Berenguer","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.11.009_b0060","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/230386","article-title":"Cyclosporine: a review","volume":"2012","author":"Tedesco","year":"2012","journal-title":"J Transplant"},{"key":"10.1016\/j.jhep.2016.11.009_b0065","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1124\/dmd.108.025544","article-title":"Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin a in rats","volume":"37","author":"Shitara","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jhep.2016.11.009_b0070","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/v5071684","article-title":"Cyclophilins as modulators of viral replication","volume":"5","author":"Frausto","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2016.11.009_b0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/117739280700200017","article-title":"Cyclophilin and viruses: cyclophilin as a cofactor for viral infection and possible anti-viral target","volume":"2","author":"Watashi","year":"2007","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.jhep.2016.11.009_b0080","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbrc.2013.12.052","article-title":"Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP","volume":"443","author":"Iwamoto","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2016.11.009_b0085","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","article-title":"Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor","volume":"60","author":"Nkongolo","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.11.009_b0090","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","article-title":"Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)","volume":"59","author":"Watashi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.11.009_b0095","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"elife"},{"key":"10.1016\/j.jhep.2016.11.009_b0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00424-013-1367-0","article-title":"Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters","volume":"466","author":"Anwer","year":"2014","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.jhep.2016.11.009_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.109.002014","article-title":"Xenobiotic, bile acid, and cholesterol transporters: function and regulation","volume":"62","author":"Klaassen","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jhep.2016.11.009_b0110","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/gutjnl-2013-304594","article-title":"Sodium-dependent taurocholic cotransporting polypeptide: a candidate receptor for human hepatitis B virus","volume":"62","author":"Seeger","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.11.009_b0115","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-3-642-14541-4_5","article-title":"The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation","author":"Stieger","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jhep.2016.11.009_b0120","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/j.gastro.2014.02.024","article-title":"Identification of NTCP as an HBV receptor: the beginning of the end or the end of the beginning?","volume":"146","author":"Tong","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.11.009_b0125","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3390\/ijms15022892","article-title":"NTCP and beyond: opening the door to unveil hepatitis B virus entry","volume":"15","author":"Watashi","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2016.11.009_b0130","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3350\/cmh.2015.21.3.193","article-title":"From DCPD to NTCP: the long journey towards identifying a functional hepatitis B virus receptor","volume":"21","author":"Li","year":"2015","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2016.11.009_b0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.antiviral.2014.03.017","article-title":"Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle","volume":"106","author":"Blanchet","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2016.11.009_b0140","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3851\/IMP2965","article-title":"The FDA approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide","volume":"20","author":"Ko","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.11.009_b0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2012.12.008","article-title":"Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes","volume":"97","author":"Lucifora","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2016.11.009_b0150","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.antiviral.2015.06.007","article-title":"Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity","volume":"120","author":"Wang","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2016.11.009_b0155","doi-asserted-by":"crossref","first-page":"11945","DOI":"10.1128\/JVI.01855-15","article-title":"A novel tricyclic polyketide, vanitaracin A, specifically inhibits the entry of hepatitis B and D viruses through targeting NTCP","volume":"89","author":"Kaneko","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2016.11.009_b0160","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.27694","article-title":"Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+) -taurocholate cotransporting polypeptide knockout mice","volume":"62","author":"Slijepcevic","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.11.009_b0165","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/hep.27240","article-title":"Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype","volume":"61","author":"Vaz","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.11.009_b0170","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.antiviral.2013.03.020","article-title":"Curing a viral infection by targeting the host: the example of cyclophilin inhibitors","volume":"99","author":"Lin","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2016.11.009_b0175","first-page":"213","article-title":"Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection","volume":"11","author":"Watashi","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.jhep.2016.11.009_b0180","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ajpath.2015.01.028","article-title":"Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice","volume":"185","author":"Ishida","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2016.11.009_b0185","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bbrc.2014.08.029","article-title":"Formation of covalently closed circular DNA in Hep38.7-Tet cells, a tetracycline inducible hepatitis B virus expression cell line","volume":"452","author":"Ogura","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2016.11.009_b0190","doi-asserted-by":"crossref","first-page":"31715","DOI":"10.1074\/jbc.M113.501122","article-title":"Interleukin-1 and tumor necrosis factor-\u03b1 trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID)","volume":"288","author":"Watashi","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2016.11.009_b0195","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1074\/jbc.M114.602540","article-title":"Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression","volume":"290","author":"Tsukuda","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2016.11.009_b0200","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitis B who require immunosuppressive therapy","volume":"11","author":"Hwang","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.11.009_b0205","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jhep.2014.05.018","article-title":"Kinetics of the bile acid transporter and hepatitis B virus receptor Na+\/taurocholate cotransporting polypeptide (NTCP) in hepatocytes","volume":"61","author":"Konig","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.11.009_b0210","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.11.009_b0215","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","article-title":"Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein","volume":"26","author":"Petersen","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2016.11.009_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117152","article-title":"Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP)","volume":"10","author":"Veloso Alves Pereira","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.11.009_b0225","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1128\/JVI.03478-13","article-title":"Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide","volume":"88","author":"Yan","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2016.11.009_b0230","doi-asserted-by":"crossref","first-page":"G829","DOI":"10.1152\/ajpgi.00352.2002","article-title":"Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake","volume":"285","author":"Hata","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2016.11.009_b0235","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0022-3565(24)35228-0","article-title":"Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity","volume":"291","author":"Kim","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2016.11.009_b0240","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.3748\/wjg.v19.i40.6730","article-title":"Virus entry mediated by hepatitis B virus envelope proteins","volume":"19","author":"Taylor","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.11.009_b0245","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.11.009_b0250","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.11.009_b0255","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1128\/AAC.49.8.3474-3482.2005","article-title":"Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist","volume":"49","author":"Takashima","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.11.009_b0260","first-page":"G157","article-title":"Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter","volume":"274","author":"Craddock","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jhep.2016.11.009_b0265","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.27960","article-title":"Alisporivir plus ribavirin, interferon-free or in combination with peg-interferon, for HCV genotype 2 or 3 infection","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816306833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816306833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T21:31:24Z","timestamp":1749763884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816306833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0168827816306833"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.11.009","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}